MA45154A - Procédés de préparation d'oligomères - Google Patents

Procédés de préparation d'oligomères

Info

Publication number
MA45154A
MA45154A MA045154A MA45154A MA45154A MA 45154 A MA45154 A MA 45154A MA 045154 A MA045154 A MA 045154A MA 45154 A MA45154 A MA 45154A MA 45154 A MA45154 A MA 45154A
Authority
MA
Morocco
Prior art keywords
preparation processes
oligomer preparation
oligomer
processes
preparation
Prior art date
Application number
MA045154A
Other languages
English (en)
Other versions
MA45154B1 (fr
Inventor
Richard K Bestwick
Bao Cai
Diane Elizabeth Frank
Mitchell Martini
Ross Shimabuku
Katie Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MA45154A publication Critical patent/MA45154A/fr
Publication of MA45154B1 publication Critical patent/MA45154B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
MA45154A 2016-05-24 2017-05-24 Procédés de préparation d'oligomères MA45154B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662341049P 2016-05-24 2016-05-24
US201662357166P 2016-06-30 2016-06-30
US201662356923P 2016-06-30 2016-06-30
US201662357072P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
EP17731336.8A EP3464305B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères
PCT/US2017/034235 WO2017205496A1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères

Publications (2)

Publication Number Publication Date
MA45154A true MA45154A (fr) 2019-04-10
MA45154B1 MA45154B1 (fr) 2024-11-29

Family

ID=59078165

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45154A MA45154B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères
MA049775A MA49775A (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA049775A MA49775A (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Country Status (21)

Country Link
US (2) US10875880B2 (fr)
EP (2) EP3564248A1 (fr)
JP (2) JP7008642B2 (fr)
KR (1) KR102506298B1 (fr)
CN (1) CN109563114B (fr)
AU (1) AU2017269355B2 (fr)
BR (2) BR122022014984B1 (fr)
CA (1) CA3025339A1 (fr)
CO (1) CO2018013838A2 (fr)
DK (1) DK3464305T3 (fr)
ES (1) ES2993738T3 (fr)
FI (1) FI3464305T3 (fr)
HR (1) HRP20241428T1 (fr)
IL (1) IL263149B2 (fr)
MA (2) MA45154B1 (fr)
MD (1) MD3464305T2 (fr)
MX (2) MX2021008539A (fr)
SA (1) SA518400500B1 (fr)
SG (1) SG10202101830WA (fr)
TW (2) TWI738784B (fr)
WO (1) WO2017205496A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
SG10202101834QA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101830WA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing oligomers
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) * 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
CN109152792B (zh) * 2016-06-30 2021-09-14 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
MA49986A (fr) 2017-09-25 2020-07-01 Massachusetts Inst Technology Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
EP3784248A4 (fr) * 2018-04-26 2022-08-10 Sarepta Therapeutics, Inc. Oligomères induisant le saut d'exon et conjugués d'oligomères pour la dystrophie musculaire
WO2024163762A2 (fr) * 2023-02-01 2024-08-08 Alnylam Pharmaceuticals, Inc. Cycle à six chaînons contenant des oligomères

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
WO1986005519A1 (fr) 1985-03-15 1986-09-25 James Summerton Reactif et procede d'analyse de polynucleotides
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE68914843T2 (de) 1988-09-01 1994-11-10 Risoe Forskningscenter Peptid-synthese und fester träger zur verwendung dabei.
CA2180253A1 (fr) 1993-12-29 1995-07-06 Atsushi Akahane Compose pyrazolopyridine antagoniste de l'adenosine
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
WO2001083740A2 (fr) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Composition anti-sens a region d'epissage et methode associee
WO2003020739A2 (fr) 2001-09-04 2003-03-13 Exiqon A/S Compositions d'acides nucleiques verrouilles et utilisations
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003291682A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
ES2645410T3 (es) * 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
DK2207779T3 (da) * 2007-11-15 2014-07-14 Sarepta Therapeutics Inc Fremgangsmåde til syntese af morpholinooligomerer
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
CN105779453A (zh) 2008-10-24 2016-07-20 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
JP2012523225A (ja) 2009-04-10 2012-10-04 アソシアシオン・アンスティテュ・ドゥ・ミオロジー 疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法
BR122023023194A2 (pt) 2009-11-12 2023-12-26 The University Of Western Australia Oligonucleotídeo antissentido, composição e respectivo uso
KR102182663B1 (ko) * 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI463423B (zh) * 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
DK2623507T3 (da) 2010-09-30 2017-01-02 Nippon Shinyaku Co Ltd Morpholinonukleinsyrederivat
CA2826836A1 (fr) * 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Oligonucleotides antisens
US9920084B2 (en) 2011-08-23 2018-03-20 The Royal Institution For The Advancement Of Learning/Mcgill University Ionic tags for synthesis of oligoribonucleotides
EP2581448B1 (fr) 2011-10-13 2015-01-28 Association Institut de Myologie ADN tricyclo-phosphorothioate
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス， インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CA3132111A1 (fr) * 2011-12-28 2013-07-04 Nippon Shinyaku Co., Ltd. Acides nucleiques antisens pour saut d'exon 55 du gene humain de la dystrophine
EP2820155B1 (fr) 2012-02-28 2017-07-26 Population Genetics Technologies Ltd. Procédé de fixation d'une contre-séquence à un échantillon d'acides nucléiques
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
HRP20190382T1 (hr) * 2013-03-14 2019-04-19 Sarepta Therapeutics, Inc. Pripravci koji preskaču ekson za liječenje mišićne distrofije
EA202090946A3 (ru) * 2013-03-14 2021-07-30 Сарепта Терапьютикс, Инк. Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
NZ631289A (en) 2013-03-15 2017-08-25 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
EP3015467B1 (fr) * 2013-05-24 2024-12-04 Ajinomoto Co., Inc. Procédé de fabrication de morpholino-oligonucléotide
SG10202101830WA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing oligomers
SG10202101834QA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) * 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
CN117298290A (zh) 2016-12-19 2023-12-29 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
LT3554553T (lt) 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
EP3554552B1 (fr) 2016-12-19 2022-08-17 Sarepta Therapeutics, Inc. Conjugués oligomères de sauts d'exons pour la dystrophie musculaire
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии

Also Published As

Publication number Publication date
SA518400500B1 (ar) 2022-09-01
EP3464305A1 (fr) 2019-04-10
TW202200599A (zh) 2022-01-01
JP2019518832A (ja) 2019-07-04
CN109563114A (zh) 2019-04-02
US20210198296A1 (en) 2021-07-01
ES2993738T3 (en) 2025-01-08
CA3025339A1 (fr) 2017-11-30
AU2017269355B2 (en) 2021-04-15
EP3564248A1 (fr) 2019-11-06
KR102506298B1 (ko) 2023-03-06
BR112018074346A2 (pt) 2019-03-06
TWI801843B (zh) 2023-05-11
JP2021176967A (ja) 2021-11-11
US20200040020A1 (en) 2020-02-06
US10875880B2 (en) 2020-12-29
IL263149B1 (en) 2023-01-01
MD3464305T2 (ro) 2025-01-31
CO2018013838A2 (es) 2019-01-18
MA45154B1 (fr) 2024-11-29
BR112018074346B1 (pt) 2023-01-03
AU2017269355A1 (en) 2019-01-17
SG10202101830WA (en) 2021-04-29
MA49775A (fr) 2020-06-10
DK3464305T3 (da) 2024-10-28
IL263149B2 (en) 2023-05-01
BR122022014984B1 (pt) 2024-03-05
FI3464305T3 (fi) 2024-10-30
MX2021008539A (es) 2022-10-18
KR20190015311A (ko) 2019-02-13
JP7008642B2 (ja) 2022-01-25
TW201806962A (zh) 2018-03-01
TWI738784B (zh) 2021-09-11
WO2017205496A1 (fr) 2017-11-30
MX2018014472A (es) 2019-05-23
MX384727B (es) 2025-03-14
CN109563114B (zh) 2022-08-12
IL263149A (en) 2019-01-31
EP3464305B1 (fr) 2024-08-21
HRP20241428T1 (hr) 2025-01-03
US11384105B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
EP3504196A4 (fr) Procédés de préparation d'olaparib
EP3706784A4 (fr) Compositions et procédés de production de lymphocytes t
MA45155A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3302575A4 (fr) Vecteurs d'édition de génome
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
EP3303413A4 (fr) Procédés de préparation de sugammadex et de ses intermédiaires
MA52906A (fr) Procédé de préparation d'amg 416
EP3458531A4 (fr) Compositions de revêtement et leurs procédés de préparation
MA45183A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3558312A4 (fr) Procédés d'amélioration de la densité vasculaire
EP3423404A4 (fr) Nouvelles compositions de germanosilicates et procédés de préparation de celles-ci
MA49775A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3383783A4 (fr) Appareil d'alimentation à porte-à-faux équilibré
MA46717A (fr) Variantes de l'endonucléase homing tcra
EP3562798C0 (fr) Procédés d'oligomérisation d'éthylène
EP3481201A4 (fr) Procédés de préparation de 4-alcoxy-3-(acyl ou alkyl)oxypicolinamides
MA42423A (fr) Procédé de préparation d'un revêtement
DK3679010T3 (da) Kulsyre-additionsprodukter
EP3500546A4 (fr) Propenylamines et leurs procédés de préparation et d'utilisation
MA45362A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine
EP3390368A4 (fr) Procédés de préparation de 5,6-dihydro-6-phénylbenzo[f]isoquinoléine-2-amine substituée
EP3265100A4 (fr) Procédés de préparation de fluorokétolides
EP3317004A4 (fr) Appareil de préparation d'une solution, et procédés associés
EP3533856A4 (fr) Procédé de préparation d'hexadécahydropyrène